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Molecular surveillance for drug-resistant malaria parasites requires reliable, timely, and scalable methods.
These data may be efficiently produced by genotyping parasite populations using second-generation sequenc-
ing (SGS). We designed and validated a SGS protocol to quantify mutant allele frequencies in the Plasmodium
falciparum genes dhfr and dhps in mixed isolates. We applied this new protocol to field isolates from children
and compared it to standard genotyping using Sanger sequencing. The SGS protocol accurately quantified dhfr
and dhps allele frequencies in a mixture of parasite strains. Using SGS of DNA that was extracted and then
pooled from individual isolates, we estimated mutant allele frequencies that were closely correlated to those
estimated by Sanger sequencing (correlations, >0.98). The SGS protocol obviated most molecular steps in con-
ventional methods and is cost saving for parasite populations >50. This SGS genotyping method efficiently and
reproducibly estimates parasite allele frequencies within populations of P. falciparum for molecular epidemio-
logic studies.
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Drug-resistant malaria parasites are widespread, under-
mine malaria control efforts, and continue to emerge in
response to the deployment of newer drugs. Through
sophisticated in vitro and animal experimentation, the
molecular correlates of antimalarial resistance in Plas-
modium falciparum have been characterized for multi-
ple drugs and have been used to describe correlations
between treatment response and individual geno-
types [1] as well as between treatment response and
prevailing genotypes [2]. The latter efforts have been
aided by large-scale meta-analyses of genotype preva-
lence surveys intended to track resistance alleles [3–5].
The prevalence of molecular markers of drug resis-
tance in populations of parasites can be estimated by
several approaches. The most common approach is to
genotype parasites from individuals using one of
several polymerase chain reaction (PCR)–based proto-
cols, classify isolates as harboring pure or mixed alleles
at the loci of interest, and compute the prevalence of
alleles and haplotypes. Several considerations under-
mine this approach’s ability to reliably quantify allele
frequencies: (1) field isolates are genetically complex
and frequently possess parasite strains with alternate
alleles; (2) mixed genotypes are usually classified as
mutant, thereby excluding significant proportions of
wild-type parasites; and (3) genotyping protocols
cannot reliably detect minority variant genotypes,
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thus underestimating low-frequency subpopulations of alleles
in mixed infections. Moreover, genotyping individual isolates is
resource intensive, and costs are directly proportional to the
number of specimens genotyped; these considerations limit
large field studies. One method of statistical inference that uses
maximum likelihood estimation (MLE) to compute allele fre-
quencies can address the multiplicity of infection (MOI) [6],
but this method requires additional genotype data and thus
more resources.
Rapid, efficient, and quantitative genotyping approaches are
needed to track the spread of molecular markers of antimalarial
resistance through parasite populations. To characterize muta-
tions conferring resistance to the antimalarial sulfadoxine-
pyrimethamine (SP), in this report we describe the develop-
ment and application of an approach that uses a second-gener-
ation sequencing (SGS) platform to quantify P. falciparum
allele frequencies in field isolates from Tanzanian children with
uncomplicated malaria using 2 distinct specimen pooling ap-
proaches. This novel approach is amenable to the efficient sur-
veillance of drug-resistance markers and can also be applied to
describe the populations of other parasite genes implicated in
immunogenicity, virulence, and transmission.
METHODS
Ethics Statement
The original trial was reviewed by ethics boards of the National
Institute for Medical Research, Dar es Salaam, Tanzania and
the Regional Ethics Committee, Stockholm, Sweden. Molecular
analyses were approved by the review board of the University of
North Carolina, Chapel Hill.
Specimen Collection
Parasites were obtained from 50 children with uncomplicated
P. falciparum malaria from Fukayosi, Bagamoyo District, Tan-
zania, enrolled in a trial of artemether-lumefantrine in 2006
[7]. Pretreatment finger-prick blood samples were collected
and stored as dried blood spots (DBSs) in individual plastic
bags. From these, genomic DNA (gDNA) was extracted by 2
approaches using a Chelex 100 method: (1) individually,
wherein 3 0.5-cm diameter disks were punched from each DBS
into separate wells of a 96-well plate and gDNA was extracted
from the DBS in each well and (2) pooled, wherein a 0.5-cm
disk was punched from each DBS into a single tube and gDNA
was extracted from the combined DBSs.
Estimating Genotype Frequencies Using Individual Sanger
Sequencing
Individual dhfr and dhps genotypes were obtained via amplifi-
cation and direct sequencing from the individual gDNA speci-
mens as described elsewhere [8], with the exception that
reaction volumes were halved and 5 µL of template was input
into the 12.5 µL primary reaction. Briefly, gDNA was subjected
to nested amplifications for both dhfr and dhps and these am-
plicons were bidirectionally sequenced using ABI Big Dye Ter-
minator chemistry (Supplementary Table 1). Reads were scored
by manual inspection of chromatograms using Sequencher
software (version 4.8; Gene Codes), and loci at which a second-
ary peak height was ≥10% of the major peak height were
scored as “mixed” infections. All specimens had been previous-
ly genotyped to determine the MOI at merozoite surface
protein 1 (msp1) and 2 (msp2) [7].
Estimating Genotype Frequencies Using Statistical Inference
We used MalHaploFreq to convert the prevalences of alleles
into frequencies after incorporation of the MOI [6], an ap-
proach that can allow for more precise frequency estimates with
limited bias [9]. We defined MOI for each individual sample as
the largest number of either msp1 ormsp2 alleles obtained.
Validation of Genotyping Using SGS
We mixed the gDNA of parasite laboratory strains 3d7 (MRA-
102G and MR4; American Type Culture Collection) and V1/S
(MRA-176G and MR4), which have contrasting dhfr and dhps
haplotypes: 3d7 harbors a wild-type dhfr haplotype (haplotype
NCSI) and A437G substitution in dhps (haplotype SGKAA),
whereas V1/S harbors 4 dhfr substitutions (haplotype IRNL)
and 3 dhps substitutions (haplotype FGKAT) (mutant amino
acid substitutions bolded). We amplified dilutions of each
gDNA in a real-time PCR assay targeting the single-copy P. fal-
ciparum gene pfldh to generate relative quantity estimates [10].
Based on these, we mixed the gDNA of 3d7 and V1/S in a ratio
of 4:1. This gDNA mixture was used as template for PCR am-
plification and 454 sequencing of dhfr and dhps amplicons.
For both dhfr and dhps, deep sequencing was performed in
duplicate, using the same template; 5 µL of the template was
input into separate primary 25-µL reactions consisting of
0.25 µL of Roche FastStart High-Fidelity Taq Polymerase, 0.5 µL
of dNTPs, 2.5 µL of Reaction Buffer, 400 nmol/L each of
forward and reverse primers, and 15.75 µL of water (Supplemen-
tary Table 1). Nested 25-µL reactions consisted of 2 µL of the
primary round product but otherwise identical constituents.
Both targets were prepared for unidirectional 454 sequencing,
however a poly(A) homopolymer in dhps required that nested
PCR reactions for dhps consist of 2 parallel reactions: one with
the sequencing tag appended to the 5′ primer and the other with
the sequencing tag appended to the 3′ primer.
Amplicons were sized using an ABI Bioanalyzer 2100 with a
high-sensitivity DNA chip (Agilent Technologies) and quanti-
fied using a Quant-iT PicoGreen dsDNA assay (Life Technolo-
gies). We sequenced dhfr and dhps in separate sequencing runs;
for each run, we multiplexed amplicons from 4–6 templates
that had been amplified with different multiplex identifiers
(MIDs), and we prepared these for sequencing following
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emulsion PCR protocols from Roche. Sequencing reads from
the 454 GS Junior were initially filtered using the platform’s
shotgun analysis, then subsequently trimmed of MIDs, tags,
and primers, and culled of low-quality reads based on previous-
ly determined cutoffs (eg, length and quality score) using an in-
house tool [11]. High-quality reads meeting these thresholds
were input into genotype frequency analyses using Lasergene
Genomics Core Suite with SeqMan NGen (version 10.0;
DNAStar). Unpaired readings were assembled into single
contigs to respective reference sequences for dhfr (GenBank
XM_001351443) or dhps (GenBank Z30654). The mutant allele
frequency at single-nucleotide polymorphism (SNP) loci was
defined as the number of mutant alleles divided by the coverage
at that locus. We adopted the conservative approach of exclud-
ing SNPs with a frequency below 1%, owing to the reported
99.1% accuracy of 454 amplicon sequencing of P. falciparum
genes [12].
Estimating Genotype Frequencies Using SGS
We performed 454 sequencing of dhfr and dhps codons from
clinical samples using 2 different templates: (1) gDNA speci-
mens that were extracted individually and pooled into a single
aliquot (with equal volumes from each individual gDNA and (2)
a gDNA specimen extracted from pooled DBSs into a single
aliquot (Figure 1). Amplicons were prepared and sequenced, and
reads were aligned and scored as above. In the clinical specimens,
we defined novel mutations as any SNP or indel that was present
in ≥1% of the total number of readings for that target [12].
Comparisons of Allele Frequencies
We computed pairwise correlation coefficients to quantify the
strength of correlation between allele frequencies generated by
the 4 approaches: Sanger, Sanger with MLE (Sanger-MLE), 454
sequencing of pooled gDNA (pooled gDNA), and 454 se-
quencing of pooled DBS (pooled DBS). Technical replicates of
the 454 sequencing reactions were included as separate fre-
quency estimations. We used a Bonferroni correction of a P
value of .05 to determine significant correlations, which were
computed with Stata/IC software (version 11; StataCorp).
We compared the estimated per-specimen cost of the se-
quencing approaches across a range of numbers of specimen.
Calculations excluded labor costs, and used the following unit
costs (US dollars) for steps in each protocol: gDNA extraction,
$2; PCR, $2; Sanger sequencing reaction, $5; 454 GS Junior se-
quencing reaction, $1100.
RESULTS
Allele Estimates in Clinical Specimens Using Traditional
Methods
From 50 clinical isolates, we obtained Sanger sequencing reads
for 50 dhfr and 46 dhps fragments. Mutant dhfr alleles were
common: 80%–88% of isolates harbored the N51I, C59R, and
S108N mutations as pure or mixed genotypes, similar to find-
ings of prior studies (Table 1) [13]. No isolates harbored the
I164L mutation in dhfr. The dhpsmutations A437G and K540E
were present in 60.0% (95% confidence interval [CI], 44.3–
74.3) and 54.3% (95% CI, 39.0–69.1) of isolates, respectively;
only 1 isolate (2.2%) harbored the 581G mutation, and none
harbored mutations in codons 436 or 613 (Table 1).
We estimated allele frequencies using an MLE method that
accounts for parasite strain multiplicity [6]. With this method,
the population frequencies of mutant alleles were slightly lower
than the above prevalences for all dhfr and dhps loci, probably
reflecting the contribution of wild-type alleles to mixed infec-
tions (Table 1).
Validation of SGS
To test the ability of deep sequencing to accurately estimate
allele frequencies, we estimated allele frequencies in a mixture
of gDNA from parasite lines 3d7 and V1/S that were mixed 4:1.
Technical replicates were carried through parallel amplification
and sequencing steps for both targets.
Sequencing of dhfr returned 26 839 and 21 420 analyzable
reads for the 2 replicates (Supplementary Table 2). The com-
bined mutant allele frequencies for dhfr were 21.7% (95% CI,
21.3%–22.1%) for N51I, 21.6% (95% CI, 21.2%–22%) for
C59R, 22.9% (95% CI, 22.5%–23.4%) for S108N, and 17.1%
(95% CI, 16.0%–18.3%) for I164L (Table 2). Sequencing of
dhps returned 1726 analyzable reads for the first replicate and
3608 for the second. The reduced yield of the first replicate was
owing to the absence of reads from the 5′ end of the amplicon,
reducing the yield of base calls at dhps codons 581 and 613.
The combined mutant allele frequencies for dhps were 20.1%
(95% CI, 21.4%–18.8%) for S436F, 100% for A437G, 0% for
K540E and A581G, and 15.5% (95% CI, 13.8%–17.3%) for
A613T (Table 2). Thus, all allele frequencies were close to ex-
pected frequencies, suggesting that deep sequencing the prod-
ucts of the PCR amplifications provides allele frequencies that
accurately estimate those within the template DNA.
Allele Estimates in Clinical Specimens With SGS
After quality filtering, the 4 replicates of pooled gDNA from
Fukayosi isolates yielded 91 157 reads of dhfr, and aggregate
read coverage at loci of interest varied from 91 155 at dhfr51 to
14 636 at dhfr164 (Supplementary Table 2). The dhps sequenc-
ing of pooled Fukayosi gDNA returned 93 638 analyzable reads
(47 836 5′ → 3′ reads and 45 802 3′ → 5′ reads); aggregate read
coverage at the codons of interest was 47 826 (dhps437), 55 956
(dhps540), and 45 606 (dhps581).
In the pooled gDNA, mutant allele frequencies in dhfr were
70.9% (95% CI, 70.6%–71.2%) for N51I, 84.6% (95% CI,
84.4%–84.9%) for C59R, 90.2% (95% CI, 90.0%–90.4%) for
S108N, and 0% for I164L (Figure 2A; Table 1). In dhps, mutant
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Figure 1. Schematic of different sequencing approaches used to characterize prevailing parasite genotypes. A, Specimens are collected from patients,
genomic DNA (gDNA) is extracted individually, target sequences are amplified individually, and polymerase chain reaction (PCR) products are sequenced
individually to obtain a sequencing read for each isolate. These reads are then used to generate a prevalence of mutant alleles or combined with an esti-
mate of each isolate’s multiplicity of infection to estimate the frequency of alleles. B, Specimens are collected from patients, gDNA is extracted individual-
ly but then combined into a gDNA pool, the target sequence is amplified from this pooled gDNA using primers adapted for second-generation sequencing
(eg, 454, Illumina), and this PCR product is sequenced on a second-generation sequencing platform to yield thousands of sequencing reads. These reads
are then aligned to a reference sequence and scored for mutations to estimate the frequency of mutant alleles. C, Specimens are collected from patients,
but gDNA is extracted in a single pool, and the procedure follows as described for B.
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allele frequencies were 55.1% (95% CI, 54.7%–55.6%) for
A437G, 57.9% (95% CI, 57.5%–58.3%) for K540E, and 6.2%
(95% CI, 6.0%–6.4%) for A581G (Figure 2B; Table 1).
In the amplicons generated from pooled DBS, mutant allele
frequencies in dhfr were 72.7% (95% CI, 72.4%–73.0%) for
N51I, 45.7% (95% CI, 45.3%–46.0%) for C59R, 96.6% (95% CI,
96.5%–96.8%) for S108N, and 0% for I164L. Mutant allele
frequencies in dhps were 54.86% (95% CI, 53.8–56) for A437G,
60.39% (95% CI, 59.5–61.3) for K540E, and 6.35% (95% CI,
5.8%–6.9%) for A581G. There were no novel mutations in the
sequenced fragments of dhfr or dhps from Sanger or SGS
readings.
Table 1. Estimates of Mutant Allele Frequencies from Clinical Specimens
Estimate (95% CI), %
Gene and Mutation Sangera Sanger–MLE 454–Pooled gDNA 454–Pooled DBS
dhfr (n = 50)
N51I 80 (66.2–90) 78.92 (63.16–100) 70.91 (70.62–71.21) 72.70 (72.38–73.02)
C59R 86 (73.3–94.2) 80.48 (64.56–100) 84.61 (84.38–84.85) 45.66 (45.30–46.02)
S108N 88 (75.7–95.5) 86.16 (67.30–100) 90.2 (89.99–90.41) 96.62 (96.47–96.77)
I164L 0 0 0 0
dhps (n = 46)
S436A NA NA 12.78 (12.48–13.08) 18.41 (17.54–19.28)
S436Y NA NA 0 0
S436F NA NA 0 0
A437G 60 (44.3–74.3)b 58.45 (43.89–82.89)b 55.11 (54.67–55.56) 54.86 (53.75–55.98)
K540E 54.3 (39–69.1) 51.14 (40.09–68.87) 57.88 (57.47–58.29) 60.39 (59.46–61.33)
A581G 2.2 (0–11.5) 1.09 (0–11.69) 6.19 (5.97–6.41) 6.35 (5.82–6.88)
A613S NA NA 0 0
A613T NA NA 0 0
Abbreviations: CI, confidence interval; DBS, dried blood spot; gDNA, genomic DNA; MLE, maximum likelihood estimation; NA, not available (chromatograms did
not adequately cover loci).
a Percentage of mixed or mutant alleles.
b n = 45.
Table 2. Mutant Allele Frequencies in a Mix of Genomic DNA From Parasite Clones 3d7 and V1/S
Gene and
Mutationa




(95% CI), % Reads, No.
Mutant Allele Frequency




N51I 26 838 21.6 (21.1–22.09) 21 419 21.83 (21.27–22.38) 48 257 21.70 (21.33–22.07) 20
C59R 26 838 21.53 (21.03–22.02) 21 419 21.72 (21.17–22.27) 48 257 21.61 (21.24–21.98) 20
S108N 19 670 22.10 (21.52–22.68) 16 148 23.90 (23.25–24.56) 35 818 22.92 (22.48–23.35) 20
I164L 2212 16.5 (14.95–18.05) 2028 17.9 (16.23–19.57) 4240 17.17 (16.03–18.30) 20
dhps
S436F 1726 20.57 (18.66–22.47) 2019 19.71 (17.98–21.45) 3745 20.11 (18.82–21.39) 20
A437G 1726 100 2019 100 3745 100 100
K540E 1662 0 3514 0 5176 0 0
A581G 1053 0 2778 0 3831 0 0
A613S 0 NA 1589 0 1589 0 0
A613T 0 NA 1589 15.54 (13.76–17.33) 1589 15.54 (13.76–17.33) 20
Abbrevations: CI, confidence interval. NA, not available (readings were not long enough to provide coverage at this locus).
a The dhfr haplotype at codons 51, 59, 108, and 164 of 3d7 is NCSI; that of V1/S is IRNL (mutant amino acid substitutions in bold). The dhps haplotype at codons
436, 437, 540, 581, and 613 of 3d7 is SGKAA; that of V1/S is FGKAT.
b Genomic DNA from clones 3d7 and V1/S was mixed at a ratio of 4:1.
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Comparative Accuracy and Cost of Genotyping Approaches
All approaches were highly correlated—with correlation coeffi-
cients >0.98—save for 1 of the replicates of the pooled DBS
SGS method (Table 3). Furthermore, these pairwise positive
correlations were largely significant; the nonsignificant correla-
tions with allele frequencies generated by pooled gDNA repli-
cates 3 and 4 are probably due to these being partial frequency
estimates, because only dhfr alleles were estimated 4 indepen-
dent times. Thus, pooling gDNA before SGS was highly corre-
lated with Sanger sequencing approaches in estimating the
frequency of mutant alleles in dhfr and dhps.
We estimated the per-specimen cost to genotype a range of
numbers of isolates at both dhfr and dhps (Figure 3). Although
the Sanger-sequencing methods were more cost-efficient than
our methods with fewer specimens, our optimal quantitative
approach (pooling gDNA specimens and sequencing ampli-
cons of dhfr and dhps in separate 454 reactions) was less costly
than Sanger sequencing at approximately 100 specimens and
less costly than a Sanger-MLE approach at only 60 specimens.
These costs are exclusive of labor costs; because the SGS ap-
proach obviates most PCR reactions, it substantially reduces
technician time owing to fewer reactions, electrophoresis steps,
and amplicon purifications. Thus, cost savings would probably
be larger than estimated if labor costs were considered.
DISCUSSION
We used a SGS platform to characterize mutant allele frequen-
cies in a population of P. falciparum parasites from Bagamoyo
Figure 2. Mutant parasite allele frequencies as estimated by various methods in dhfr (A) and dhps (B). Mutant allele frequencies in dhfr and dhps as es-
timated by 454 second-generation sequencing (SGS) in a 80:20 mixture of parasite strains 3d7 and V1/S (white bars), by Sanger sequencing of individual
parasite isolates from children in Fukayosi, Tanzania (checkerboard bars), by maximum likelihood estimation (MLE) based on Sanger sequencing of child-
ren’s parasite isolates (striped bars), by SGS of pooled genomic DNA (gDNA) from children’s parasite isolates (light gray bars), and by SGS of pooled dried
blood spots (DBSs) from children’s parasite isolates (dark gray bars). Lines indicate 95% confidence intervals based upon the proportion of alleles either
within the isolates or within the reads. Numbers in parentheses indicate technical replicates of the SGS protocol.
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district, Tanzania. In our assay validation, SGS of PCR products
generated from a template of a known ratio of parasite strains
returned allele frequency estimates very close to the expected
frequencies. Moreover, the allele frequencies generated from
SGS of field parasites were similar to those generated from
conventional Sanger sequencing, at comparable cost. Because it
can return reliable, replicable allele frequencies and is scalable
to larger cohorts of specimens, pooled SGS of malaria para-
sites offers a new method by which to accurately and efficient-
ly characterize P. falciparum genotypes for epidemiologic
surveillance.
Second-generation amplicon sequencing offers the ability to
characterize and quantify complex genotypes within a single
specimen. Previous field studies of malaria parasites have used it
to classify recurrent parasitemias after drug therapy [12], describe
the diversity of vaccine-targeted parasite antigens [11, 14, 15],
and quantify resistance alleles within a single isolate [16]. In
these studies, when compared with conventional methods, SGS
was better able to capture “minority variants” or low-frequency
subpopulations. Our approach extends these applications by ap-
plying this sequencing technology to amplicons generated from
pooled gDNA that represents a defined population of parasites.
Therefore, the sequencing reads represent genotypes present in
the original mixture and are aggregate frequency estimates across
the population.
How sensitive is this approach for the detection of low-level
alleles? A concern with any sequencing approach is the possible
loss of the ability to detect ”minority variant” subpopulations,
which could undermine surveillance for drug-resistance alleles.
Statistical genetic models predict that pooled sequencing with
adequate coverage (ie, large number of reads per individual) will
detect minor alleles more often than individual sequencing [17].
Indeed, our sequencing of clinical isolates consistently returned
>10 000 reads covering each locus, and the corresponding clini-
cal sensitivity of our pooled SGS approach seemed high: our ap-
plication to clinical specimens from Tanzania allowed detection
of the A581G mutation in dhps that was present in only 1 of 46
(2.2%) isolates by Sanger sequencing; with SGS, this mutation
was present in 4.5%–6.3% in the reads from 4 replicates prepared














Sanger . . . <.0001 .0002 .0001 .2004 .2686 .0008 1
Sanger-MLE 0.9992 . . . .0005 .0003 .2935 .3629 .0017 1
Pooled gDNA (1) 0.9929 0.9902 . . . <.0001 .0126 .0219 <.0001 1
Pooled gDNA (2) 0.9943 0.9916 0.9994 . . . .0130 .0296 <.0001 1
Pooled gDNA (3)b 0.9928 0.9895 0.9995 0.9995 . . . .0056 .0067 1
Pooled gDNA (4)b 0.9904 0.9870 0.9992 0.9989 0.9998 . . . .0011 1
Pooled DBS (1) 0.9880 0.9842 0.9991 0.9983 0.9998 1 . . . 1
Pooled DBS (2) 0.6264 0.6503 0.6370 0.6257 0.5482 0.5510 0.6259 . . .
Abbreviations: DBS, dried blood spot; gDNA, genomic DNA; MLE, maximum likelihood estimation;
a Numbers in lower half are correlation coefficients between estimates of mutant allele frequencies in dhfr (codons 51, 59, 108, and 164) and dhps (codons 437,
540, and 581); numbers close to 1 indicate a positive correlation, those close to −1 indicate a negative correlation, and those close to 0 indicate no correlation
between values in the 2 groups. Correlation coefficients that were significant at P < .05 after Bonferroni correction are bolded and italicized. Numbers in upper half
of table are P values for the correlation coefficients. Numbers in parentheses indicate technical replicates of the second-generation sequencing reactions.
b Frequencies are available only for the 4 dhfr loci, because dhpswas sequenced in only only 2 replicates.
Figure 3. Estimated cost of various methods used to genotype parasite
isolates at dhfr and dhps. Estimated costs are exclusive of labor. Input
costs (US dollars) per unit used in calculations were as follows: genomic
DNA (gDNA) extraction, $2; polymerase chain reaction, $2; Sanger se-
quencing reaction, $5; 454 GS Junior second-generation sequencing reac-
tion, $1100. Abbreviations: DBS, dried blood spot; MLE, maximum
likelihood estimation.
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by 2 approaches. We suspect this discrepancy reflects the ability
of SGS to better capture these genotypes when present as minori-
ty variants in complex mixtures. These observations suggest that
our sequencing approach can be applied to detect emerging ge-
notypes within diverse parasite populations owing to its high
clinical sensitivity.
Overall, our estimates of mutant allele frequencies are similar
if slightly lower than those reported from contemporary studies
in Northeastern Tanzania [13, 18, 19]. A notable exception to
this is the low frequency of dhps A581G mutations in our study,
which contrasts with prevalences >50% in 2 studies from the
mid-2000s in towns close to our study site to the north [18, 19].
The in vivo significance of this mutation remains undetermined:
although parasites bearing the A581G mutation were associated
with reduced effectiveness of sulfadoxine-pyrimethamine as an-
tenatal preventive therapy[16] and as therapy for uncomplicated
childhood malaria [19], allelic exchange experiments suggest that
this substitution alone does not substantially affects the parasite’s
in vitro susceptibility to SP [20]. This mutation’s geographic
range and clinical impact in ecologic studies can be further
defined using our approach to genotyping parasites.
We applied SGS to 2 separate templates that were derived
from field specimens: gDNA that was individually extracted and
then pooled in equal volumes (pooled gDNA) and gDNA that
was extracted from pooled DBSs in a single extraction (pooled
DBS; Figure 1). Between approaches, mutant allele frequencies
were similar at most loci except for dhfr59; at this locus, poor
dhfr readings were obtained from 1 of 2 sequencing replicates
obtained from the pooled DBS template, probably because ho-
mopolymers (such as that containing this substitution) are prone
to return errors on SGS platforms. Because of this, the correla-
tion of 1 of the 2 replicates of pooled DBS readings was very
poor (Table 3). Aside from this subset of sequencing readings, all
methods were highly correlated in their estimation of mutant
allele frequencies, although this discrepancy highlights a need
for technical replicates of SGS reactions. Furthermore, because
most laboratories will require individual gDNA aliquots for
other applications, we recommend amplification and SGS of
pooled gDNA for allele frequency estimation.
For genotyping studies designed to quantify allele frequencies
in >50 specimens, our approach is cost-effective when compared
to the conventional approach of individual Sanger sequencing
(Figure 3). A sequencing reaction on a second-generation plat-
form is far more expensive than one on a Sanger platform, but
this cost is offset by the obviation of most PCR reactions by the
pooled approach, as well as by the great reduction in the number
of sequencing reactions needed for pooled genotyping. Two
further points merit mention. First, hands-on technician time is
also greatly reduced by pooled deep sequencing, principally
owing to the obviation of most PCR assays, agarose gels, and am-
plicon purifications. This may provide further cost savings that
were not included in our calculations. Second, pooled deep
sequencing can be applied to large numbers of isolates without
sacrificing cost-effectiveness, and, in fact, becomes far less costly
than conventional approaches with more isolates. Thus our new
approach is easily scalable without sacrificing cost-effectiveness.
Pooled deep sequencing can quantify allele frequencies
quickly and efficiently in large populations of malaria parasites
and thus has many applications for molecular epidemiologic in-
vestigations. As we demonstrate, surveillance for mutations con-
ferring parasite drug resistance is a manifest application and can
be easily used when molecular markers of parasite drug resis-
tance are well described. This is the case for multiple drugs. in-
cluding sulfadoxine and pyrimethamine (as measured herein),
chloroquine, amodiaquine, and lumefantrine. Currently, no mo-
lecular marker for prolonged parasite clearance time in response
to artemisinin has been described, although recent reports have
associated this parasite phenotype with mutations on P. falcipa-
rum chromosomes 10 [21] and 13 [21, 22]; PCR-based genotyp-
ing protocols have been promulgated for 2 of the mutations [23]
and could be adapted to SGS to define the limits of its circulation
in parasite populations. Beyond drug-resistance markers, this ap-
proach can be adapted to characterize any SNP-based parasite
genotype that confers clinically significant phenotypes, such as
those associated with infection severity or transmissibility.
Although promising, our study and method are subject to
several limitations. Using this SGS approach, we were unable to
quantify dhps haplotypes, owing to an inability to consistently
sequence through a homopolymer in the dhps gene between
codons 437 and 540. Second, this approach precludes the investi-
gation of parasite mutations and individual response to therapy.
Moreover, we pooled equal volumes of gDNA from isolates, and
therefore allele frequencies may be biased by differences in vivo
parasite densities and extraction efficiency; however, extractions
were performed uniformly to minimize variability, and the ex-
clusion of children with reported recent sulfadoxine-pyrimeth-
amine (SP) intake would be expected to minimize potential bias
of parasite density by dhfr and dhps haplotype. Finally, this ap-
proach is cost-effective in operation compared with individual
genotyping; though it requires new infrastructure including
access to a SGS platform and analytic software, these resources
are increasingly available at academic medical centers or through
outside vendors.
Pooled SGS of malaria parasites offers an efficient and scalable
approach to quantifying drug-resistance alleles in parasite popu-
lations. With this approach, many parasites can be genotyped
rapidly and quantitatively for molecular surveillance of drug-
resistance alleles. Additional applications include characterizing
the genotypes of parasite antigens targeted by vaccines and those
associated with virulence or transmission. This approach is
readily adaptable to large-scale drug-resistance surveillance, and
further molecular ecologic studies will be necessary to investigate
associations between prevailing genotype frequencies and in vivo
drug efficacy.
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